The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Diagnosis and treatment of Parkinson disease: molecules to medicine
Open accessAbstract
Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder that affects at least 1% of people by age 70 (1-3).James Parkinson provided the first detailed description of the disease in his 1817 monograph "An Essay on the Shaking Palsy."In the latter part of the nineteenth century, Charcot further refined the description of this disorder and identified the cardinal clinical features of PD including rest tremor, rigidity, balance impairment, and slowness of movement (reviewed in ref. 4).An early clue to the pathology of the disease came from Brissaud, who speculated that damage in the substantia nigra (SN) might lead to PD (5, 6).Eosinophilic inclusions (Lewy bodies) later were identified in the brains of PD patients (7) and, along with abnormalities in the SN, became a recognized pathologic marker of the disease (8).A major advance in the understanding of PD came when dopamine deficiency was discovered in the corpus striatum and SN of brains taken from patients (9).Later studies demonstrated the connection between the SN and the striatum, thus suggesting that dopaminergic cell loss in the SN directly leads to dopaminergic deficiency in the striatum (10).The determination that PD is a disease of dopamine loss led to the development of ratio-nal therapies aimed at correcting this deficiency (11).After some initial uncertainty, the dopamine precursor levodopa proved to be a powerful PD treatment (12).Subsequent advances in therapy included combining levodopa with a peripheral decarboxylase inhibitor, such as carbidopa or benserazide (13, 14).This combination significantly reduced the nausea and vomiting associated with levodopa therapy and allowed a greater proportion of levodopa to enter the brain.Similarly, catechol-O-methyltransferase (COMT) inhibitors, which prolong the half-life of levodopa and dopamine were found to enhance the effect of a given levodopa dose (15-17).In addition to increasing the level of dopamine precursors, the focus of therapeutic design was also on limiting the breakdown of endogenous dopamine.The monoamine oxidase type B (MAO-B) inhibitor selegiline works in this fashion and provides symptomatic benefit (18).Finally, the development of dopamine agonists that directly stimulate postsynaptic dopamine receptors, thus bypassing dopamine synthesis completely, further illustrates how novel therapies can be borne from knowledge of pathology (19,20).Surgical therapies that reduce tremor and rigidity in PD patients were used prior to the advent of levodopa treatment.Meyers pioneered surgical lesioning procedures that targeted symptoms and spared patients from the hemiparesis that resulted from earlier surgical approaches.These procedures largely were abandoned once levodopa therapy became more common (21).Recent advances in the understanding of basal ganglia physiology and the development of new technologies has led to a reemergence of surgical PD therapies in the form of deep brain stimulation (DBS) (22,23).DBS has become increasingly common in patients whose disease is difficult to manage with medical therapy alone.Despite these landmark advances in symptomatic PD therapy, the ability of these treatments to facilitate an acceptable quality of life for the patient wanes with time.This is due to the development of motor complications including wearing-off (the Diagnosis and treatment of Parkinson disease: molecules to medicine
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 2×
“Lewy bodies and neurites stain with antibodies to α-synuclein, ubiquitin, and a variety of other biochemical markers and are found in many areas of the PD brain: not only the SN, but also the dorsal motor nucleus of the vagus, locus ceruleus, raphe and reticular formation nuclei, thalamus, amygdala, olfactory nuclei,…”
BackgroundHughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683
Frequency Dependence of Signal Power and Spatial Reach of the Local Field Potential
Leski, S., Lindén, H., Tetzlaff, T., Pettersen, K. H., & Einevoll, G. T. (2013) · PubMed · doi:10.18154/rwth-conv-084442 · Cited by 3,639
Cited by
PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1
Geisler, S., Holmström, K. M., Skujat, D., Fiesel, F. C., Rothfuss, O. C., Kahle, P. J., & Springer, W. (2010) · Nature Cell Biology · doi:10.1038/ncb2012 · Cited by 2,835
“dtd" [ ]> Parkinson's disease is the most common movement disorder and results from selective and massive loss of dopamine-containing neurons in the Substantia Nigra pars compacta (SNpc”
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Shin, J.-H., Ko, H. S., Kang, H., Lee, Y., Lee, Y.-I., Pletinkova, O., Troconso, J. C., Dawson, V. L., & Dawson, T. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.010 · Cited by 953
Self-citationGenetic Animal Models of Parkinson's Disease
Dawson, T. M., Ko, H. S., & Dawson, V. L. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.034 · Cited by 823
A review on graphene-based nanocomposites for electrochemical and fluorescent biosensors
Krishnan, S. K., Singh, E., Singh, P., Meyyappan, M., & Nalwa, H. S. (2019) · RSC Advances · doi:10.1039/c8ra09577a · Cited by 785
Animal models of neurodegenerative diseases
Dawson, T. M., Golde, T. E., & Lagier-Tourenne, C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0236-8 · Cited by 576
Hypocretin (orexin) cell loss in Parkinson's disease
Thannickal, T. C., Lai, Y.-Y., & Siegel, J. M. (2007) · Brain · doi:10.1093/brain/awm097 · Cited by 566
DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers
Lippa, C. F., Duda, J. E., Grossman, M., Hurtig, H. I., Aarsland, D., Boeve, B. F., Brooks, D. J., Dickson, D. W., Dubois, B., Emre, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000256715.13907.d3 · Cited by 548
Manoharan, S., Guillemin, G. J., Abiramasundari, R. S., Essa, M. M., Akbar, M., & Akbar, M. D. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/8590578 · Cited by 523
Lin, X., Parisiadou, L., Gu, X.-L., Wang, L., Shim, H., Sun, L., Xie, C., Long, C.-X., Yang, W.-J., Ding, J., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.11.006 · Cited by 518
PINK1/PARKIN signalling in neurodegeneration and neuroinflammation
Quinn, P. M. J., Moreira, P. I., Ambrósio, A. F., & Alves, C. H. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01062-w · Cited by 481
Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery
Lee, V. M.-Y., & Trojanowski, J. Q. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.026 · Cited by 479
NOX Enzymes in the Central Nervous System: From Signaling to Disease
Sorce, S., & Krause, K.-H. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2578 · Cited by 471
Hypocretin (orexin) loss in Parkinson's disease
Fronczek, R., Overeem, S., Lee, S. Y. Y., Hegeman, I. M., van Pelt, J., van Duinen, S. G., Lammers, G. J., & Swaab, D. F. (2007) · Brain · doi:10.1093/brain/awm090 · Cited by 463
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E., & Lee Mosley, R. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0507296 · Cited by 420
The role of parkin in familial and sporadic Parkinson's disease
Dawson, T. M., & Dawson, V. L. (2010) · Movement Disorders · doi:10.1002/mds.22798 · Cited by 392
Imaizumi, Y., Okada, Y., Akamatsu, W., Koike, M., Kuzumaki, N., Hayakawa, H., Nihira, T., Kobayashi, T., Ohyama, M., Sato, S., et al. (2012) · Molecular Brain · doi:10.1186/1756-6606-5-35 · Cited by 380
Manganese and Parkinson’s Disease: A Critical Review and New Findings
Guilarte, T. R. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.0901748 · Cited by 357
HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
Simões-Pires, C., Zwick, V., Nurisso, A., Schenker, E., Carrupt, P.-A., & Cuendet, M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-7 · Cited by 341
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics
Shaw, L. M., Korecka, M., Clark, C. M., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2176 · Cited by 339
Johnson, M. E., & Bobrovskaya, L. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2014.12.002 · Cited by 332
Sun, C.-L., Chang, C.-T., Lee, H.-H., Zhou, J., Wang, J., Sham, T.-K., & Pong, W.-F. (2011) · ACS Nano · doi:10.1021/nn2015908 · Cited by 328
S-Glutathionylation: From Molecular Mechanisms to Health Outcomes
Xiong, Y., Uys, J. D., Tew, K. D., & Townsend, D. M. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3540 · Cited by 314
“ubiquitin and a-synuclein containing Lewy bodies are considered hallmarks of the disease (74) and it has been suggested that oxidative damage or misfolded proteins can initiate the formation of Lewy bodies that ultimately cause dopamine neuronal degeneration (242).”
BackgroundOxidative and nitrosative stress in Parkinson's disease
Tsang, A. H. K., & Chung, K. K. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.12.006 · Cited by 300
“form of PD whereas mutations in LRRK2, like α-syn, cause autosomal dominant PD [39].”
BackgroundInfluentialYarjanli, Z., Ghaedi, K., Esmaeili, A., Rahgozar, S., & Zarrabi, A. (2017) · BMC Neuroscience · doi:10.1186/s12868-017-0369-9 · Cited by 296
Ko, H. S., Lee, Y., Shin, J.-H., Karuppagounder, S. S., Gadad, B. S., Koleske, A. J., Pletnikova, O., Troncoso, J. C., Dawson, V. L., & Dawson, T. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006083107 · Cited by 283
Tang, F.-L., Erion, J. R., Tian, Y., Liu, W., Yin, D.-M., Ye, J., Tang, B., Mei, L., & Xiong, W.-C. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0042-15.2015 · Cited by 269
Tang, F.-L., Liu, W., Hu, J.-X., Erion, J. R., Ye, J., Mei, L., & Xiong, W.-C. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.001 · Cited by 269
Karuppagounder, S. S., Brahmachari, S., Lee, Y., Dawson, V. L., Dawson, T. M., & Ko, H. S. (2014) · Scientific Reports · doi:10.1038/srep04874 · Cited by 264
Sanchez-Guajardo, V., Febbraro, F., Kirik, D., & Romero-Ramos, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008784 · Cited by 256
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis
Banerjee, R., Starkov, A. A., Beal, M. F., & Thomas, B. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.11.007 · Cited by 253
Blazer, L. L., & Neubig, R. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.151 · Cited by 197
Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts
Fellner, L., Jellinger, K. A., Wenning, G. K., & Stefanova, N. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0833-z · Cited by 162
Nicotine and Parkinson's disease: implications for therapy
Quik, M., O'Leary, K., & Tanner, C. M. (2008) · Movement Disorders · doi:10.1002/mds.21900 · Cited by 154
“In summary, the inverse relationship between Parkinson’s disease and smoking appears consistent with a true biological protective effect of tobacco use, based on findings that: (1) it is observed in large prospective cohort studies; (2) is stronger in current compared to former smokers; (3) is correlated with smoking…”
BackgroundInfluentialZhang, S., Wang, X.-J., Tian, L.-P., Pan, J., Lu, G.-Q., Zhang, Y.-J., Ding, J.-Q., & Chen, S.-D. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-154 · Cited by 154
“However, emerging investigations suggest that multiple factors, both genetic and acquired, contribute to the loss of dopaminergic cells in the substantia nigra (SN) of these patients [2-4].”
BackgroundLoh, H. W., Ooi, C. P., Palmer, E., Barua, P. D., Dogan, S., Tuncer, T., Baygin, M., & Acharya, U. R. (2021) · Electronics · doi:10.3390/electronics10141740 · Cited by 144
Ahmed, I., Liang, Y., Schools, S., Dawson, V. L., Dawson, T. M., & Savitt, J. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0209-12.2012 · Cited by 144
“Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized pathologically by the extensive loss of dopamine neurons in the substantia nigra pars compacta (SNpc) and the presence of dystrophic neurites and Lewy bodies in the surviving neurons (Savitt et al., 2006).”
BackgroundSelf-citationHook, P. W., McClymont, S. A., Cannon, G. H., Law, W. D., Morton, A. J., Goff, L. A., & McCallion, A. S. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.02.001 · Cited by 136
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys
Quik, M., Cox, H., Parameswaran, N., O'Leary, K., Langston, J. W., & Di Monte, D. (2007) · Annals of Neurology · doi:10.1002/ana.21203 · Cited by 133
Expert systems: Definitions, advantages and issues in medical field applications
Saibene, A., Assale, M., & Giltri, M. (2021) · Expert Systems with Applications · doi:10.1016/j.eswa.2021.114900 · Cited by 133
Divino da Rocha, M., Pereira Dias Viegas, F., Cristina Campos, H., Carolina Nicastro, P., Calve Fossaluzza, P., Alberto Manssour Fraga, C., J. Barreiro, E., & Viegas, C. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711794480429 · Cited by 126
Haleagrahara, N., & Ponnusamy, K. (2010) · The Journal of Toxicological Sciences · doi:10.2131/jts.35.41 · Cited by 123
“Though levodopa is the treatment of choice in PD, there are motor complications and oxidative neuronal damage reported with continuous therapy (Lan and Jiang, 1997; Savitt et al., 2006).”
BackgroundReprogramming the epigenome with vitamin C
Lee Chong, T., Ahearn, E. L., & Cimmino, L. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00128 · Cited by 120
Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease
Marella, M., Seo, B. B., Nakamaru-Ogiso, E., Greenamyre, J. T., Matsuno-Yagi, A., & Yagi, T. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001433 · Cited by 116
Kolk, S. M., Gunput, R.-A. F., Tran, T. S., van den Heuvel, D. M. A., Prasad, A. A., Hellemons, A. J. C. G. M., Adolfs, Y., Ginty, D. D., Kolodkin, A. L., Burbach, J. P. H., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2521-09.2009 · Cited by 114
“Changes in mdDA connectivity cause drastic behavioral deficits and underlie neural disorders such as Parkinson’s disease and schizophrenia (Winterer and Weinberger, 2004; Savitt et al., 2006), highlighting the need to understand how these precise connections are established and maintained.”
BackgroundChung, Y. C., Kim, Y.-S., Bok, E., Yune, T. Y., Maeng, S., & Jin, B. K. (2013) · Mediators of Inflammation · doi:10.1155/2013/370526 · Cited by 94
Olivares, D., Huang, X., Branden, L., Greig, N. H., & Rogers, J. T. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10031226 · Cited by 93
Yan, Q., Han, C., Wang, G., Waddington, J. L., Zheng, L., & Zhen, X. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.109512 · Cited by 77
Neely, M. D., Schmidt, D. E., & Deutch, A. Y. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.06.044 · Cited by 80
Sun, S., Han, X., Li, X., Song, Q., Lu, M., Jia, M., Ding, J., & Hu, G. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00381 · Cited by 77
Nam, J. H., Leem, E., Jeon, M.-T., Jeong, K. H., Park, J.-W., Jung, U. J., Kholodilov, N., Burke, R. E., Jin, B. K., & Kim, S. R. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8729-2 · Cited by 76
Khezeli, T., & Daneshfar, A. (2015) · RSC Advances · doi:10.1039/c5ra08058d · Cited by 66
Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson’s disease
Cuevas, E., Burks, S., Raymick, J., Robinson, B., Gómez-Crisóstomo, N. P., Escudero-Lourdes, C., Lopez, A. G. G., Chigurupati, S., Hanig, J., Ferguson, S. A., et al. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1859729 · Cited by 57
Extracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation
Chavarría, C., Ivagnes, R., & Souza, J. M. (2022) · Biomolecules · doi:10.3390/biom12050655 · Cited by 47
“α-Syn is a small protein composed of 140 amino acids (14 KDa) and is abundant in many regions of the brain [16,17].”
BackgroundWu, Z., Xia, Y., Wang, Z., Su Kang, S., Lei, K., Liu, X., Jin, L., Wang, X., Cheng, L., & Ye, K. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0687-7 · Cited by 41
Metadata
- Authors
- Savitt, J. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1744-1754
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1986118996
- Cited by
- 650
- References
- 124
- FWCI
- 21.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.